Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cardax, Inc. (CDXI)
Honolulu, HI, US
Cardax, Inc. is a biopharmaceutical enterprise focused on both creating and marketing nutritional supplements for maintaining inflammatory well-being, as well as developing pharmaceutical treatments for chronic ailments rooted in inflammation and oxidative stress. Its product portfolio includes ZanthoSyn, an advanced supplement for inflammation, health, and longevity that delivers astaxanthin with superior absorption and purity. This product is primarily distributed through online sales and wholesale channels. The company is also progressing two pharmaceutical candidates: CDX-101, an astaxanthin-derived drug candidate intended to address cardiovascular inflammation and dyslipidemia, with a primary focus on severe hypertriglyceridemia; and CDX-301, a zeaxanthin-based pharmaceutical currently under development for macular degeneration. Cardax, Inc. maintains its headquarters in Honolulu, Hawaii.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +9,900.00% | +0.00% | +0.00% | +0.00% | -50.00% | -99.99% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-24.2% Q1'21: -26.8% (vs Q1'20)
-
EPS growth Biotechnology: +29.7%+19.2% Q1'21: -10.6% (vs Q1'20)
-
FCF margin FCF growth · Biotechnology: +16.2%-740.0% Q1'21: -323.1% (vs Q1'20)
-
EBIT margin Biotechnology: +0.0%-495.6% Q1'21: -902.6% (vs Q1'20)
-
ROIC Biotechnology: -16.1%— Q1'21: +62.8% (vs Q1'20)
-
Share dilution Biotechnology: -3.4%+9.5% Q1'21: +13.3% (vs Q1'20)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.81× Q1'21: -1.44× (vs Q1'20)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-02-24 | Paulson Cardax Investments 1 LLC | Director | P-Purchase | A | Common Stock | 500,000 | 0.20 | 100.0K | 1,300,000 | — | ↗ |
| 2014-02-24 | PAULSON CAPITAL (DELAWARE) CORP. | 10% Owner | P-Purchase | A | Common Stock | 500,000 | 0.20 | 100.0K | 1,300,000 | — | ↗ |
| 2014-02-07 | Paulson Cardax Investments 1 LLC | Director | J-Other | A | Warrants (right to buy) | 1,068,477 | 0.00 | — | 1,068,477 | — | ↗ |
| 2014-02-07 | PAULSON CAPITAL (DELAWARE) CORP. | 10% Owner | — | I | Warrants (right to buy) | 3,872,434 | 0.63 | 2.42M | 0 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David Watumull | Chairman & Chief Executive Officer | 215.0K | male |
| Gilbert Shin | Vice President of Retail Sales & Marketing | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CDXI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
